U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C24H24N4O5S
Molecular Weight 480.536
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of KI-20227

SMILES

COC1=CC2=C(C=C1OC)C(OC3=CC(OC)=C(NC(=O)NC(C)C4=NC=CS4)C=C3)=CC=N2

InChI

InChIKey=SHPFDGWALWEPGS-UHFFFAOYSA-N
InChI=1S/C24H24N4O5S/c1-14(23-26-9-10-34-23)27-24(29)28-17-6-5-15(11-20(17)30-2)33-19-7-8-25-18-13-22(32-4)21(31-3)12-16(18)19/h5-14H,1-4H3,(H2,27,28,29)

HIDE SMILES / InChI
Molecular Formula C24H24N4O5S
Molecular Weight 480.536
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18085662

KI20227 is a potent and orally active inhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R) (IC50 values are 2, 12, 217 and 451 nM for c-Fms, VEGFR-2, PDGFRβ and c-Kit respectively). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Ki20227 suppresses experimental autoimmune encephalomyelitis. Ki20227 may be a useful therapeutic agent for osteolytic disease associated with bone metastasis and other bone diseases. Ki20227 and its derivatives may also be candidate drugs for the treatment of human multiple sclerosis. Ki20227 is currently in the preclinical developlent stage.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 2.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
2006 Nov
The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model.
2008 Jan
Patents

Patents

US20140235631
1
US7598258
1

Sample Use Guides

In Vivo Use Guide
Rats: Ki20227 (20 mg/kg/d) was given orally once per day for 28 days to 6-week-old female Sprague-Dawley rats
Route of Administration: Oral
In Vitro Use Guide
Growth of M-NFS-60 cells in medium supplemented with 3% FCS and 50 ng/mL M-CSF was almost completely suppressed by treatment with 100 nmol/L of Ki20227.
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:00:49 GMT 2023
Edited
by admin
on Sat Dec 16 08:00:49 GMT 2023
Record UNII
T4W68CAT3P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
KI-20227
Code English
KI20227
Systematic Name English
UREA, N-(4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)-2-METHOXYPHENYL)-N'-(1-(2-THIAZOLYL)ETHYL)-
Systematic Name English
N-(4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)-2-METHOXYPHENYL)-N'-(1-(2-THIAZOLYL)ETHYL)UREA
Systematic Name English
1-(4-(6,7-DIMETHOXYQUINOLIN-4-YL)OXY-2-METHOXYPHENYL)-3-(1-(1,3-THIAZOL-2-YL)ETHYL)UREA
Systematic Name English
KI-20227, (±)-
Code English
Code System Code Type Description
EPA CompTox
DTXSID80432108
Created by admin on Sat Dec 16 08:00:49 GMT 2023 , Edited by admin on Sat Dec 16 08:00:49 GMT 2023
PRIMARY
PUBCHEM
9869779
Created by admin on Sat Dec 16 08:00:49 GMT 2023 , Edited by admin on Sat Dec 16 08:00:49 GMT 2023
PRIMARY
FDA UNII
T4W68CAT3P
Created by admin on Sat Dec 16 08:00:49 GMT 2023 , Edited by admin on Sat Dec 16 08:00:49 GMT 2023
PRIMARY
CAS
623142-96-1
Created by admin on Sat Dec 16 08:00:49 GMT 2023 , Edited by admin on Sat Dec 16 08:00:49 GMT 2023
PRIMARY
Related Record Type Details
Structure of KI-20227, (R)-
ENANTIOMER -> RACEMATE
Structure of KI-20227, (S)-
ENANTIOMER -> RACEMATE
Related Record Type Details
Structure of KI-20227
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966